Shares of ResMed (NYSE:RMD) traded 1.44 points or 2.41% higher at $61.29.The total intraday money flow for the shares came in at a disappointing $(-2.04) million. The total upticks amounted to $3.91 million and the total downticks were approximately $5.95 million, with the up/down ratio of 0.66. On a different note, the shares have seen 5.02% price change during the week.In a block trade which occurred during the day, the stock had an inflow of $0 million in upticks and an outflow of $2.07 million in downticks. The up/down ratio for the block was found to be 0. The net money flow for the block transaction was $(-2.07) million.
The stock has recorded a 20-day Moving Average of 4.51% and the 50-Day Moving Average is 5.85%. The company shares have rallied 5.44% in the past 52 Weeks. On April 25, 2016 The shares registered one year high of $61.23 and one year low was seen on August 24, 2015 at $48.99. The 50-day moving average is $58.19 and the 200 day moving average is recorded at $57.18. S&P 500 has rallied 1.93% during the last 52-weeks.
ResMed (NYSE:RMD): During Tuesdays trading session, Bulls were in full control of the stock right from the opening. The stock opened at $60.52 and $60.32 proved to be the low of the day. Continuous buying at higher levels pushed the stock towards an intraday high of $61.96. The buying momentum continued till the end and the stock did not give up its gains. It closed at $61.78, notching a gain of 3.22% for the day. The total traded volume was 1,517,555 . The stock had closed at $59.85 on the previous day.
Currently the company Insiders own 2.54% of ResMed shares according to the proxy statements. Institutional Investors own 58.75% of ResMed shares. During last six month period, the net percent change held by insiders has seen a change of -13.03%. On the companys insider trading activities,The officer (Chief Executive Officer) of Resmed Inc, Farrell Michael J. sold 5,975 shares at $59.63 on June 15, 2016. The Insider selling transaction had a total value worth of $356,289. The Insider information was disclosed with the Securities and Exchange Commission in a Form 4 filing.
ResMed Inc. is engaged in the development, manufacturing, distribution and marketing of medical products for the diagnosis, treatment and management of respiratory disorders, with a focus on sleep-disordered breathing (SDB). The Company develops various products for SDB and other respiratory disorders, including airflow generators, diagnostic products, mask systems, headgear and other accessories. It produces continuous positive airway pressure, variable positive airway pressure and AutoSet systems for the titration and treatment of SDB. Its products also include S9 Escape, AirSense 10 Elite, AirSense 10 CPAP, S9 VPAP S, S9 VPAP ST, S9 VPAP Adapt, S9 VPAP ST-A, S9 VPAP COPD and AirCurve 10 V Auto, among others. It markets sleep recorders for the diagnosis and titration of SDB in sleep clinics and hospitals. Its products include Quattro FX, Swift FX for Her, Mirage FX for Her, Pixi Pediatric Mask, Quattro FX for Her, Swift FX Bella, Swift FX Nano, AirFit N10 and Apnealink Air.